These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 31575640)
1. Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial. Dovc K; Piona C; Yeşiltepe Mutlu G; Bratina N; Jenko Bizjan B; Lepej D; Nimri R; Atlas E; Muller I; Kordonouri O; Biester T; Danne T; Phillip M; Battelino T Diabetes Care; 2020 Jan; 43(1):29-36. PubMed ID: 31575640 [TBL] [Abstract][Full Text] [Related]
2. Short-term fully closed-loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes. Bally L; Herzig D; Ruan Y; Wilinska ME; Semmo M; Vogt A; Wertli MM; Vogt B; Stettler C; Hovorka R Diabetes Obes Metab; 2019 Dec; 21(12):2718-2722. PubMed ID: 31464063 [TBL] [Abstract][Full Text] [Related]
3. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion. Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial. Bode BW; Iotova V; Kovarenko M; Laffel LM; Rao PV; Deenadayalan S; Ekelund M; Larsen SF; Danne T Diabetes Care; 2019 Jul; 42(7):1255-1262. PubMed ID: 31076415 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial. Mathieu C; Bode BW; Franek E; Philis-Tsimikas A; Rose L; Graungaard T; Birk Østerskov A; Russell-Jones D Diabetes Obes Metab; 2018 May; 20(5):1148-1155. PubMed ID: 29316130 [TBL] [Abstract][Full Text] [Related]
6. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study. Boughton CK; Hartnell S; Thabit H; Poettler T; Herzig D; Wilinska ME; Ashcroft NL; Sibayan J; Cohen N; Calhoun P; Bally L; Mader JK; Evans M; Leelarathna L; Hovorka R Diabetes Obes Metab; 2021 Jun; 23(6):1389-1396. PubMed ID: 33606901 [TBL] [Abstract][Full Text] [Related]
7. Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial. Elleri D; Biagioni M; Allen JM; Kumareswaran K; Leelarathna L; Caldwell K; Nodale M; Wilinska ME; Haidar A; Calhoun P; Kollman C; Jackson NC; Umpleby AM; Acerini CL; Dunger DB; Hovorka R Diabetes Obes Metab; 2015 Dec; 17(12):1173-9. PubMed ID: 26257323 [TBL] [Abstract][Full Text] [Related]
8. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039 [TBL] [Abstract][Full Text] [Related]
9. Postprandial Glucose Excursions with Ultra-Rapid Insulin Analogs in Hybrid Closed-Loop Therapy for Adults with Type 1 Diabetes. Haliloglu B; Boughton CK; Lakshman R; Ware J; Nwokolo M; Thabit H; Mader JK; Bally L; Leelarathna L; Wilinska ME; Allen JM; Hartnell S; Evans ML; Hovorka R Diabetes Technol Ther; 2024 Jul; 26(7):449-456. PubMed ID: 38315506 [No Abstract] [Full Text] [Related]
10. DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control by comparing the MD-Logic automated insulin delivery system to sensor augmented pump therapy in patients with type 1 diabetes at home. Biester T; Nir J; Remus K; Farfel A; Muller I; Biester S; Atlas E; Dovc K; Bratina N; Kordonouri O; Battelino T; Philip M; Danne T; Nimri R Diabetes Obes Metab; 2019 Apr; 21(4):822-828. PubMed ID: 30478937 [TBL] [Abstract][Full Text] [Related]
11. Comparison between preprandial vs. postprandial insulin aspart in patients with type 1 diabetes on insulin pump and real-time continuous glucose monitoring. Thuillier P; Sonnet E; Alavi Z; Roudaut N; Nowak E; Dion A; Kerlan V Diabetes Metab Res Rev; 2018 Sep; 34(6):e3019. PubMed ID: 29749032 [TBL] [Abstract][Full Text] [Related]
12. A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9). Lane WS; Favaro E; Rathor N; Jang HC; Kjærsgaard MIS; Oviedo A; Rose L; Senior P; Sesti G; Soto Gonzalez A; Franek E Diabetes Care; 2020 Aug; 43(8):1710-1716. PubMed ID: 32209647 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. Ruan Y; Elleri D; Allen JM; Tauschmann M; Wilinska ME; Dunger DB; Hovorka R Diabetologia; 2015 Apr; 58(4):687-90. PubMed ID: 25537835 [TBL] [Abstract][Full Text] [Related]
14. Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial. Stewart ZA; Wilinska ME; Hartnell S; O'Neil LK; Rayman G; Scott EM; Barnard K; Farrington C; Hovorka R; Murphy HR Diabetes Care; 2018 Jul; 41(7):1391-1399. PubMed ID: 29535135 [TBL] [Abstract][Full Text] [Related]
15. The "Glucositter" overnight automated closed loop system for type 1 diabetes: a randomized crossover trial. Nimri R; Danne T; Kordonouri O; Atlas E; Bratina N; Biester T; Avbelj M; Miller S; Muller I; Phillip M; Battelino T Pediatr Diabetes; 2013 May; 14(3):159-67. PubMed ID: 23448393 [TBL] [Abstract][Full Text] [Related]
16. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1). Russell-Jones D; Bode BW; De Block C; Franek E; Heller SR; Mathieu C; Philis-Tsimikas A; Rose L; Woo VC; Østerskov AB; Graungaard T; Bergenstal RM Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319 [TBL] [Abstract][Full Text] [Related]
17. Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial. Heise T; Zijlstra E; Nosek L; Rikte T; Haahr H Diabetes Obes Metab; 2017 Feb; 19(2):208-215. PubMed ID: 27709762 [TBL] [Abstract][Full Text] [Related]
18. Investigation of Pump Compatibility of Fast-Acting Insulin Aspart in Subjects With Type 1 Diabetes. Zijlstra E; Demissie M; Graungaard T; Heise T; Nosek L; Bode B J Diabetes Sci Technol; 2018 Jan; 12(1):145-151. PubMed ID: 28918652 [TBL] [Abstract][Full Text] [Related]
19. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. Home PD; Lindholm A; Hylleberg B; Round P Diabetes Care; 1998 Nov; 21(11):1904-9. PubMed ID: 9802741 [TBL] [Abstract][Full Text] [Related]
20. Day-and-Night Hybrid Closed-Loop Insulin Delivery in Adolescents With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial. Tauschmann M; Allen JM; Wilinska ME; Thabit H; Stewart Z; Cheng P; Kollman C; Acerini CL; Dunger DB; Hovorka R Diabetes Care; 2016 Jul; 39(7):1168-74. PubMed ID: 26740634 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]